Our study indicates that targeting the PI3K pathway in the context of the lymphangiogenic pathway (VEGFR-3) may provide additional clinical benefit via the inhibition of lymph node metastasis. This evidence concerns the gene FLT4 and metastatic malignant neoplasm in the lymph nodes.